Dual Antagonist Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$606M

Range: $322M - $878M

Total Deal Value

$3.2B

Range: $2.0B - $4.4B

Royalty Rate

14.2% - 23.7%

Tiered up to 27.7%

Dev Milestones

$511M

Range: $328M - $697M

Model Your Deal

Market Analysis

Dual Antagonist therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 dual antagonist asset in immunology & autoimmune is $606M, with total deal values reaching $3.2B. Development milestones average $511M, while regulatory milestones contribute $894M.

The immunology & autoimmune dual antagonist landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for dual antagonist immunology & autoimmune deals range from 14.2% to 23.7% at the base tier, with tiered escalation reaching 18.2%-27.7% on blockbuster sales. Commercial milestones averaging $1.1B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a dual antagonist immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 dual antagonist licensing deals in immunology & autoimmune average $606M in upfront payments, with a range of $322M to $878M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for dual antagonist immunology & autoimmune transactions?

The median total deal value for Phase 2 dual antagonist assets in immunology & autoimmune is $3.2B, ranging from $2.0B to $4.4B. This includes development milestones ($511M), regulatory milestones ($894M), and commercial milestones ($1.1B).

What royalty rates are standard for dual antagonist deals in immunology & autoimmune?

Base royalty rates for dual antagonist immunology & autoimmune transactions range from 14.2% to 23.7%, with tiered escalations reaching 18.2%-27.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in dual antagonist immunology & autoimmune deals?

Dual Antagonist immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($511M) make up the largest share, followed by commercial milestones ($1.1B) and regulatory milestones ($894M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included